Skip to main content

Table 1 Cohort characteristics (n = 1303)

From: Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis

Characteristic Values
Female 1125 (86.3%)
Race
 Caucasian 1178 (90.4%)
 Asian 59 (4.5%)
 Aboriginal-Islander 15 (1.2%)
 Other 18 (1.4%)
Disease subtype
 Limited 974 (74.8%)
 Diffuse 329 (25.2%)
 Age at scleroderma onset, years 46.40 ± 14.26
 Age at recruitment, years 57.71 ± 12.54
 Disease duration at recruitment, years 11.26 ± 10.31
 Duration of follow-up, years 3.46 ± 2.69
 Ever smoked 639 (49.0%)
Autoantibodies
 ANCA 116 (8.9%)
 Anti-Scl-70 181 (13.9%)
 Anti-centromere 613 (47.0%)
 Antinuclear antibody 1222 (93.8%)
 Rheumatoid factor 337 (25.9%)
 Anti-Ro 87 (6.7%)
 Anti-La 20 (1.5%)
 Anti-RNP 26 (2.0%)
 Anti-dsDNA 42 (3.2%)
 Anti-Sm 8 (0.6%)
 Anti-Jo-1 7 (0.5%)
 Anti-Scl/PM 15 (1.2%)
 Anti-cardiolipin 262 (20.1%)
 Anti-beta 2 glycoprotein 94 (7.2%)
 Lupus anti-coagulant 35 (2.7%)
 Anti-RNA polymerase 116 (8.9%)
Clinical characteristics and complications
 Pulmonary arterial hypertension 163 (12.5%)
 Interstitial lung disease 311 (23.9%)
 Renal crisis 35 (2.7%)
 Digital ulcers 646 (49.6%)
 SIBO 37 (2.8%)
 GAVE 112 (8.6%)
 Oesophageal dysmotility 132 (10.1%)
 Oesphageal stricture 146 (11.2%)
 Synovitis 517 (39.7%)
 Malignancy 252 (19.3%)
 Hospitalisation 490 (37.6%)
 Deep vein thrombosis (DVT) 91 (7.0%)
 Pulmonary embolus (PE) 46 (3.5%)
 Overlap features with another connective tissue disease 76 (5.8%)
 Overlap syndrome with rheumatoid arthritis 27 (2.1%)
 Overlap syndrome with polymyositis 13 (1.0%)
 Overlap syndrome with Sjogren’s 24 (1.8%)
 Overlap syndrome with SLE 12 (0.9%)
 Overlap syndrome with dermatomyositis 1 (0.1%)
Treatments
 Prednisolone 580 (44.5%)
 Azathioprine 105 (8.1%)
 Mycophenolate 103 (7.9%)
 Cyclophosphamide 118 (9.1%)
 Calcium channel antagonist 847 (65.0%)
 Topical vasodilator 105 (8.1%)
 Iloprost 161 (12.4%)
 Penicillamine 108 (8.3%)
 Rituximab 11 (0.8%)
 Abatacept 1 (0.1%)
 TNF alpha inhibitor 11 (0.8%)
 Tocilizumab 5 (0.4%)
 Biologics 26 (2.0%)
  1. Values are given as number (%), mean ± SD or median (IQR)
  2. Abbreviations: ANA anti nuclear antibodies, ANCA anti-neutrophil cytoplasmic antibodies, anti-phospholipid antibodies: any one or combination of anti-cardiolipin, anti-beta-2-glycoprotein and lupus anticoagulant, anti-dsDNA anti-double stranded deoxyribonucleic acid, anti-RNP ribonucleoprotein, SIBO small intestinal bacterial overgrowth, SLE systemic lupus erythematosus, anti-Sm anti-Smith